Increased blood pressure or transient pyrexia may be observed with treatment. Use with caution in adrenal insufficiency, anemia, history of asthma, cardiovascular disease, compromised (scarred) uterus, diabetes mellitus, renal impairment, or seizure disorder. Concomitant use of antiemetic and antidiarrheal agents is recommended to decrease incidence of gastrointestinal side-effects. Large amounts of benzyl alcohol have been associated with toxicity (fatal «gasping syndrome») in neonates. Proliferation of long bones reported in neonates receiving long-term therapy with alprostadil (prostaglandin E~1~); no evidence that short-term administration of carboprost has similar effects on bone. Potent oxytocic agent. Carboprost does not affect the fetoplacental unit. Risk of cervical trauma. Transient fever (i.e. temperature elevations >1.1°C) reported in approximately 12.5% of patients. When used for termination of pregnancy, may be difficult to distinguish drug-induced temperature elevations from post-abortion endometritis. Chorioamnionitis may contribute to postpartum uterine atony and hemorrhage; individuals with chorioamnionitis experiencing postpartum hemorrhage have failed to respond to carboprost.